Pathward extends partnership with Clair to expand earned wage advance access
Bitget2026/10/08 12:07Pathward Financial extended its partnership with earned wage advance fintech Clair to widen access to advances embedded in payroll platforms. Pathward will keep originating Clair’s wage advances, reinforcing its role as the banking and lending infrastructure provider. Clair cited a $2 billion wage-advance volume run rate, 500,000 monthly active users, and more than 300,000 active businesses. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pathward Financial Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261008986894) on October 08, 2026, and is solely responsible for the information contained therein.
- Pathward Financial extended its partnership with earned wage advance fintech Clair to widen access to advances embedded in payroll platforms.
- Pathward will keep originating Clair’s wage advances, reinforcing its role as the banking and lending infrastructure provider.
- Clair cited a $2 billion wage-advance volume run rate, 500,000 monthly active users, and more than 300,000 active businesses.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Forex Today: US flash Consumer Sentiment and Canadian jobs in the limelight
Malaysian Ringgit: Fiscal anchor case – MUFG
Nasdaq Drops Over 300 Points After OpenAI's Revenue Comes In $20 Billion Short
BUZZ-Revolution Medicines stock drops due to concerns over pancreatic cancer drug data
On October 8, Revolution Medicines (RVMD.O) shares fell 8.1% in afternoon trading to $185.91. RBC Capital Markets stated that the share price decline appeared to be driven by the latest U.S. Food and Drug Administration (FDA) review documents regarding the company's pancreatic cancer drug Rasonque, particularly the disclosure of objective response rate data for specific RAS mutation subgroups. RBC pointed out that overall survival, rather than objective response rate, is a more meaningful indicator of efficacy, and that the sell-off overlooked Rasonque's broad activity across a variety of RAS mutation subgroups. RBC stated: "While we acknowledge that today's share price decline takes place against the backdrop of overall weakness in the biotech sector, we still believe that the market's reaction to the FDA review documents is an overreaction, given that the drug was approved on the basis of highly clinically meaningful efficacy and has received positive feedback from physicians." Including intraday fluctuations, the stock has more than doubled year-to-date. (Note: For the convenience of non-English speakers, Reuters has automatically translated its reports into several other languages. Automated translations may be inaccurate or lack necessary context; Reuters does not guarantee the accuracy of these automated translations and provides them only for reader convenience. Reuters does not accept liability for any damage or loss arising from the use of automated translation features.)
Crypto prices
More
